Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

University Hospital Gasthuisberg, Leuven, Belgium.

Survival: monthsCountry:Belgium
Toxiciy Grade:5City/State/Province:Leuven
Treatments:ChemotherapyHospital:University Hospital Gasthuisberg
Drugs:Journal:Link
Date:Apr 2011

Description:

Patients:
This phase II study involved previously treated metastatic colorectal cancer patients who were divided into two separate treatment groups. Group A consisted of 426 patients with a median age of 60.5 years and 62% were male. Group B had 429 patients with a median age of 59.2 years and 62.5% male.

Treatment:
Patients in group A were treated with the biologic therapy agent PTK/ZK (also known as vatalanib; an angiogenesis inhibitor that inhibits blood supply to the tumor) in addition to the chemotherapy agents oxaliplatin, fluorouracil, and leucovorin.

Patients in group B were treated with the chemotherapy agents oxaliplatin, fluorouracil, and leucovorin only.

Toxicities:
Treatment-related deaths were reported in group A, although specific causes were not given. Grade 3-4 neutropenia, high blood pressure, diarrhea, and dizziness were also reported.

Treatment-related deaths were also reported in group B, although specific causes were not given. Grade 3-4 neutropenia, diarrhea, and fatigue were also reported.

Results:
The median overall survival for groups A and B was 13.1 and 11.9 months, respectively.

Support:
This study was supported by Novartis Pharmaceuticals and Bayer Schering Pharma.

Correspondence: Dr. Eric Van Cutsem; email: [email protected]



Back